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Abstract
Intestinal Na+-coupled glucose transporter SGLT1
determines the rate of glucose transport, which in turn
influences glucose-induced insulin release and
development of obesity. The present study explored
effects of Gum Arabic (GA), a dietary polysaccharide
from dried exudates of Acacia senegal, on intestinal
glucose transport and body weight in wild-type C57Bl/
6 mice. Treatment with GA (100 g/l) in drinking water
for four weeks did not affect intestinal SGLT1 transcript
levels but decreased SGLT1 protein abundance in
jejunal brush border membrane vesicles. Glucose-
induced jejunal short-circuit currents revealed that
GA treatment decreased electrogenic glucose
transport. Drinking a 20% glucose solution for four
weeks significantly increased body weight and fasting
plasma glucose concentrations, effects significantly
blunted by simultaneous treatment with GA. GA further
significantly blunted the increase in body weight,
fasting plasma glucose and fasting insulin
concentrations during high fat diet. In conclusion, the
present observations disclose a completely novel
effect of gum arabic, i.e. its ability to decrease
intestinal SGLT1 expression and activity and thus to
counteract glucose-induced obesity.
Introduction
Gum Arabic (GA) is a water-soluble dietary fiber
derived from the dried gummy exudates of the stems and
branches of Acacia senegal [1]. Chemically, GA is a
polysaccharide based on branched chains of (1-3) linked
β-D-galactopyranosyl units. Side chains of 2-5 units in
length are attached by (1-6) links to the main chain. Both,
the main chain and the side chains contain α-L-
arabinofuranosyl, α-L-rhamnopyranosyl, β-D-glucurono-
pyranosyl and 4-O-methyl-β-D-glucuronopyranosyl units
[2]. GA is readily soluble in water without increasing
viscosity [3].
GA is widely used as an emulsifier and stabilizer by
the pharmaceutical and the food industry. It is primarily
indigestible for both humans and animals, and after passing
the small intestine it is fermented under the influence of
microorganisms in the colon to short chain fatty acids
[4]. The US Food and Drug Administration recognized it
as one of the safest dietary fibers [5].
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GA exhibits pharmacological effects related to
interference with gastrointestinal absorption of nutrients.
In a previous study we could show that GA blunted
intestinal absorption of Na+ and water in healthy mice
while enhancing calcium and magnesium uptake [6]. In a
rat model of chronic osmotic-diarrhea, GA exerted pro-
absorptive properties by increased sodium and water
absorption [7-9]. Thus, we hypothesized that GA
treatment may also influence the intestinal glucose
absorption, which is mainly accomplished by the Na+-
coupled glucose transporter SGLT1 [10]. To test this
hypothesis, we utilized gene array analysis and/or western
blotting to quantify the expression of SGLT1 as well as
known modulators of intestinal Na+-coupled glucose
transport such as RS1 (RSC1A1) [11], serum- and
glucocorticoid-inducible kinase isoforms SGK1 and SGK3
[12] in small intestine from wild-type C57Bl/6 mice. We
further determined electrogenic glucose transport in small
intestine and investigated, whether GA treatment
influences hyperglycemia, hyperinsulinemia and body
weight gain following ingestion of glucose-rich or high
fat diet.
Materials and  Methods
Gum Arabic
GA in powder form was a generous gift from Dar Savanna
Ltd., Khartoum, Sudan. It is a 100% natural extract powder
produced mechanically from the wildly grown Acacia senegal
tree with a particle size less than 210 µm. The quality con-
formed to the food and pharmaceutical requirements of the
Food and Agriculture Organization of the United Nations (FAO),
British pharmacopoiea (BP), United States pharmacopoiea
(USP) and Joint FAO/WHO Expert Committee On Food Addi-
tives (JECFA).
Animals
Experiments were carried out in male 8-12 week old wild-
type C57Bl/6 mice (Charles River, Germany). The animals were
housed under controlled environmental conditions (22-24°C,
50-70% humidity and a 12-h light/dark cycle). Throughout the
study mice had free access to standard pelleted food containing
4.5% crude fiber (C1310, Altromin, Lage, Germany) and tap water
or Gum Arabic solution as indicated. All animal experiments
were conducted according to the German law for the care and
welfare of animals and had been approved by local authorities.
Animal experimentation
Animals were provided with a control diet (C1310, 4 kcal%
fat, 0.25% Na+, 0.36% Cl-, 0.71% K+, Altromin, Heidenau,
Germany) or a high fat diet (C1000, 45 kcal% fat, 0.25% Na+,
0.36% Cl-, 0.71% K+, modified according D12451 from Research
Diet, Altromin, Heidenau, Germany) and received 10% (w/v)
GA dissolved in tap water (100 g/l) as indicated; preparations
were refreshed every 3 days during the treatment.
Glucose and insulin concentrations were determined in
blood drawn after tail-vein bleeding. Plasma glucose was
determined using a glucometer after overnight fasting
(Accutrend, Roche, Mannheim, Germany); plasma insulin was
measured using an ELISA (Crystal Chem INC, USA).
To investigate the effects of GA treatment on the
development of hyperglycemia, hyperinsulinemia and obesity
following excessive glucose intake, mice were housed
individually and 20% (w/v) glucose added to the drinking water
either with or without 10% GA. Control groups received tap
water or 10% GA. During the treatment for 4 weeks, body
weight, food and fluid intake were monitored.
Gene array analysis
To investigate the effect of GA treatment on intestinal
gene expression, whole genome gene expression profiling was
performed in intestinal tissue of untreated mice and of mice
treated with GA for one week (each n = 5). 1 µg of total RNA
was linearly amplified and biotinylated using the One-Cycle
Target Labeling Kit (Affymetrix, Santa Clara, CA, USA)
according to the manufacturer’s instructions. 15 µg of labeled
and fragmented cRNA was hybridized to MOE 430 2.0 mouse
whole genome Gene Chip® arrays (Affymetrix). After
hybridization the arrays were washed and stained in a Fluidics
Station 450 (Affymetrix) with the recommended washing
procedure. Biotinylated cRNA bound to target molecules was
detected with streptavidin-coupled phycoerithrin, biotinylated
anti-streptavidin IgG antibodies and again streptavidin-coupled
phycoerithrin according to the protocol. Arrays were scanned
using the GCS3000 Gene Chip scanner (Affymetrix) and GCOS
1.4 software. Scanned images were subjected to visual
inspection to control for hybridization artifacts and proper grid
alignment and analyzed with Microarray Suite 5.0 (Affymetrix)
to generate report files for quality control.
For statistical data analysis the CEL-files were imported
into Genespring 7.1 (Agilent Technologies, Santa Clara, CA)
using Genespring’s implementation of GC-RMA for
normalization and probe summarization. For all transcripts the
average change in expression (fold change) and the p-value
using Welch’s t-test was calculated. The effect of GA treatment
on the expression of selected transcripts was examined.
Immunoblotting of SGLT1 from small intestine
The intestinal membrane expression of SGLT1 was
determined in brush-border membrane vesicles (BBMV)
prepared from untreated mice, mice treated with GA for four
weeks, mice treated with 20% glucose for four weeks and mice
treated with both 10% GA and 20% glucose for four weeks
using the Mg2+ precipitation technique [13]. Briefly, mice were
killed with CO2 and the whole intestine was removed and divided
into two parts. After discarding the first 2 cm as duodenum the
next 13 cm were considered as jejunum and the remainder as
ileum. Jejunum and ileum were opened longitudinally. Contents
were washed out with ice-cold PBS. The epithelial layer was
scraped off with a glass slide in a buffer containing (in mM) 250
sucrose, 20 Tris (pH 7.5), 5 EGTA and a protease inhibitor
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cocktail (Roche, Mannheim, Germany). The suspension was
homogenized with a Sorvall Omnimixer (rotating blade). MgCl2
was added to the homogenate yielding a final concentration of
10 mM. The suspension was stirred on ice and then centrifuged
at 1,600 g for 15 min. The plasma membranes retained in the
supernatant were collected by centrifugation at 20,000 g for 30
min. The resultant pellet was suspended in a pH 7.4 buffer
consisting of (in mM) 125 sucrose, 10 Tris (pH 7.5), 2.5 EGTA,
2.5 MgSO4. This suspension was homogenized with 50 up-
down strokes using a glass homogenizer and centrifuged at
20,000 g for 30 min. The final pellet containing the purified
BBMV was homogenized by passing the suspension through
25- and 28-gauge needles and solubilised. All steps were carried
out at 4°C. Samples from three animals per group were pooled
and frozen for later use. Western blotting was performed in
three to four independent experiments, resulting in a total of n
= 9-12 mice in each group.
After measurement of the total protein concentration
(Biorad Protein kit), 30 µg of brush border membrane protein
were solubilized in Laemmli sample buffer at 95°C for 5 min, and
SDS-Page was performed on 10% polyacrylamide gels. For
immunoblotting, proteins were transferred electrophoretically
from unstained gels to polyvinylidene difluoride membranes
(Immobilon-P, Millipore, Bedford, MA, USA). After blocking
with 5% milk powder in Tris-buffered saline/0.1% Tween-20 for
60 min, the blots were incubated with affinity purified rabbit
anti-mouse SGLT1 antibody (1:2000; 55 kDa, Chemicon,
Temecula, CA, USA) overnight at 4°C. After washing blots
were incubated with secondary antibodies linked with horse
radish peroxidase (goat anti-rabbit 1: 2000 Cell Signaling, USA)
for 1 h at room temperature. Antibody-binding was detected
with the ECL Western blotting detection kit (RPN 2106 GE health
care, UK). Bands were quantified using Quantity One Software
(Biorad, München, Germany).
To identify the specificity of the band, the control peptide
was applied. The diluted control peptide (1:1000, AG661
Chemicon, US) was mixed with  the SGLT1 antibody for 30 min
at room temperature before incubation with the other blot, which
was done in parallel.
To provide the loading control the blot was stripped in
stripping buffer (Roth, Karlsruhe, Germany) at 56°C for 30 min.
After washing with TBST, the blot was blocked with TBST +
5% milk for 1 h at room temperature, then incubated with rabbit
anti-mouse β-actin antibody (1:1000, Cell Signaling) at 4°C over
night. After washing the blots were incubated with secondary
antibodies linked with horse radish peroxidase (goat anti-rab-
bit 1: 2000, Cell Signaling), for 1 h at room temperature. Anti-
body-binding was detected with the ECL Western blotting
detection kit (RPN 2106 GE health care, UK). Bands were quan-
tified with Quantity One Software (Biorad, München, Germany).
Ussing chamber experiments in small intestine
For the analysis of electrogenic intestinal glucose
transport, Ussing chamber experiments were performed in mice
after 1 week treatment with or without GA. Following treatment
mice were killed by cervical dislocation and the intestine was
quickly removed. Jejunal segments (5-10 cm postpylorus) were
mounted into a custom-made mini-Ussing chamber with an
opening diameter of 0.99 mm and an opening area of 0.00769
cm2. Under control conditions, the serosal and luminal perfusate
contained (in mM) 105 NaCl, 2 KCl, 1 MgCl2, 1.25 CaCl2, 0.4
KH2PO4, 1.6 K2HPO4, 5 Na pyruvate, 25 NaHCO3, and 20
mannitol. Where indicated, 10 or 20 glucose, 20 L-glutamine, 20
L-phenylalanine, 20 L-proline or 20 L-methionine were added
to the luminal perfusate at the expense of mannitol. All solutions
were gassed with 95% O2-5% CO2 for at least 60 min until usage
in the experiment. GA was not present in any of the substrate
solutions of GA-treated mice. All substances were from Sigma
(Schnelldorf, Germany) or Roth (Karlsruhe, Germany).
Statistics
Data are provided as means ± SEM, n represents the
number of independent experiments. All data were tested for
significance with one-way ANOVA followed by Tukey-Kramer
post-test, or unpaired Student’s t-test, as appropriate using
GraphPad InStat version 3.00 for Windows 95, GraphPad
Software, San Diego, California, USA. A p-value < 0.05 was
considered statistically significant.
Results
To determine, whether treatment with GA influences
the transcript levels of SGLT1 and/or regulators of the
carrier, gene array analysis was performed prior to and
following GA treatment for one week. As listed in table
1, GA treatment did not significantly modify SGLT1
transcript levels. The transcript levels of SGK1, a known
stimulator of SGLT1 [14], were even significantly
increased. However, GA treatment significantly
decreased the transcript levels of SGK3, another known
stimulator of SGLT1 [14] and increased the transcript
Table 1. Gene array analysis of major genes involved
in intestinal glucose uptake. Relative change in
expression of the respective transcript after one week
of GA treatment (n= 5 chips each).
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levels of RSC1, a known transcriptional and
posttranscriptional inhibitor of SGLT1 [11]. GLUT2
mRNA expression was not changed significantly under
GA treatment (Table 1).
In a second step, Western blotting was utilized to
clarify, whether GA treatment influences SGLT1 protein
expression (Fig. 1A). Immunoblotting of brush-border
membranes indeed disclosed significantly decreased
SGLT1 protein abundance in jejunum. In ileum, GA
treatment tended to similarly decrease SGLT1 expression,
an effect, however, not reaching statistical significance.
(Fig. 1B).
The influence of GA treatment on SGLT1 protein
abundance in jenunal brush border membranes prompted
us to study the interaction of GA with the intestinal
absorption of glucose by determining electrogenic glucose
transport in jejunal segments. In untreated mice, the
transepithelial potential difference (Vt,p) and the
transepithelial resistance (Rt,p) amounted to 1.08 ± 0.06
Fig. 1. Effect of GA on SGLT1 protein abundance in
brush-border membrane vesicles from jejunum and
ileum. Original western blots showing SGLT1 and actin
protein abundance in preparations of jejunum (A) and
ileum (B) from untreated mice, mice treated with either
gum arabic (GA) or glucose (glc) or both for four weeks.
The right panels depict the arithmetic means ± SEM
(n = 3-4) of the relative intensity of the SGLT1 protein
band. * indicates statistically significant difference
(p<0.05; paired t-test).
Fig. 2. Effect of GA treatment on intestinal electrogenic
substrate transport. A Original tracings (left) and arithmetic
means (right) of the effect of GA treatment on glucose-induced
short-circuit current (Iglc) in untreated mice with (solid bar) or
without (open bar) 10% GA in the perfusate. Due to the high
viscosity experiments were conducted with 10 mM glucose. B
Original tracings (left) and arithmetic means (right) of the effect
of GA on glucose-induced short-circuit current (Iglc) in untreated
mice (open bar) and mice treated with GA for one week (solid
bar). Note that in those experiments GA was not added to the
perfusate. C Arithmetic means ± SEM of amino acid-induced
short circuit currents (IAA) in proximal jejunum from untreated
mice (open bars) and GA-treated mice (solid bars; unpaired t-
test, p<0.05). *indicates significant difference between control
and GA treatment.
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Fig. 3. Effect of GA treatment on fasting blood glucose and plasma insulin concentrations. A & B: Arithmetic
means ± SEM of fasting blood glucose and plasma insulin concentrations in mice treated with tap water
(control, n = 10), GA (n = 12), 20% glucose and glucose + GA (n = 20 each). # indicates significant difference
between control and glucose treatment, ¶indicates significant difference between GA and glucose + GA
treatment, §indicates significant difference between glucose and glucose + GA treatment.
mV and 8.33± 0.46 Ω·cm2 (n = 7), respectively.  The
isoosmotic replacement of mannitol by glucose generated
a lumen-negative shift of the transmural potential
difference without significantly altering the transmural
resistance. The glucose-induced alterations of
transepithelial voltage and transepithelial resistance
allowed the calculation of the glucose-induced short-circuit
current Iglc. In jejunal segments of untreated mice, Iglc
amounted to -1636 ± 112 µA/cm2 at 20 mM glucose.
Addition of 10 % GA to the luminal perfusate of intestinal
segments from untreated mice did not significantly modify
glucose-induced short-circuit currents, indicating that GA
did not directly interfere with luminal glucose or the carrier
(Fig. 2A). However, as shown in Fig. 2B, GA treatment
for 1 week decreased glucose-induced short-circuit
current to -1179 ± 148 µA/cm2 without altering Vt,p (1.01
± 0.06 mV, n =6) or Rt,p (7.74 ± 0.29 Ω·cm2, n = 6).
To explore whether GA interferes with other sodium-
coupled transport processes, amino acid-induced currents
were studied in addition. As shown in Figure 2C, GA
treatment did not significantly alter the electrogenic
transport of glutamine, proline, phenylalanine and
methionine. Hence, GA treatment rather selectively
inhibited intestinal glucose absorption.
Fig. 4. Effects of GA treatment on
glucose-induced obesity. A & B:
Arithmetic means ± SEM of mean daily
fluid and food intake in untreated mice
(n = 11) and mice treated with either GA
(n = 12) or glucose (n = 20) or both
glucose and GA (n = 20) for four weeks
(one way-ANOVA with Tukey´s post-
test, p<0.0001). C Arithmetic means ±
SEM of the body weight gain during a 4
week treatment of mice with tap water,
with GA, with 20% glucose or with
glucose + GA. D Arithmetic means ± SEM
of total body weight gain after a 4 week
treatment with GA, with 20% glucose or
with glucose + GA. #indicates significant
difference between control and glucose
treatment, ¶indicates significant
difference between GA and glucose+GA
treatment, §indicates significant
difference between glucose and
glucose+GA treatment.
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To test, whether the decreased intestinal SGLT1
activity influenced plasma glucose and insulin levels as
well as body weight during excessive glucose ingestion,
mice were treated for one week with tap water, 10% GA
or a 20% (w/v) glucose solution with or without 10%
GA. Prior to treatment with glucose, the plasma glucose
concentration was not significantly different between GA-
treated mice and control mice (Fig. 3A). Addition of 20%
glucose to the drinking water significantly increased blood
glucose concentrations, an effect significantly blunted by
additional GA treatment. Excessive glucose intake tended
to increase plasma insulin levels, an effect, however, not
reaching statistical significance. The plasma insulin levels
following excessive glucose intake tended to be lower in
GA-treated animals, an effect, however, again not
statistically significant (Fig. 3B).
Further experiments were performed to investigate
the course of body weight under high glucose intake with
Fig. 5. Effect of GA treatment on fasting blood glucose, plasma insulin concentrations and obesity during
high fat diet. A Arithmetic means ± SEM of mean daily food intake in untreated mice (n = 4) as well as mice
treated with either GA (n=4) or high fat diet (HFD, n = 8) or both HFD and GA (n = 8) for 10 weeks. B: Arithmetic
means ± SEM of fasting blood glucose and plasma insulin concentrations in mice treated with HFD or HFD +
GA. C: Arithmetic means ± SEM of the body weight gain during 10 weeks in untreated mice as well as in mice
treated with either GA (n = 4) or high fat diet (HFD, n = 8) or both HFD and GA (n = 8). D Arithmetic means ±
SEM of total body weight gain within 10 weeks in untreated mice as well as in mice treated with either GA, with
HFD or with both HFD and GA. *indicates significant difference between control and GA treatment #indicates
significant difference between control and HFD treatment, ¶indicates significant difference between GA and
HFD+GA treatment.
or without GA for 4 weeks. Addition of glucose
significantly increased fluid intake and decreased food
intake to a similar extent in animals treated without or
with GA (Fig. 4A, 4B). As shown in Figure 4C&D,
administration of GA significantly blunted the body weight
gain of mice drinking 20% glucose solution.
To test, whether GA is similarly effective in high fat
diet, the body weight was monitored in animals receiving
a high fat diet with or without GA. The treatment with
GA did not significantly affect daily fluid intake (data not
shown) and was followed by a slight, but significant
decrease of food intake (Fig. 5A). As illustrated in Figure
5B, high fat diet was paralleled by hyperglycemia and
hyperinsulinism, effects significantly blunted by GA
treatment. Moreover, the treatment was followed by body
weight gain, which was significantly blunted following GA
treatment (Fig. 5 C&D).
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Discussion
The present study reveals that GA decreases the
membrane abundance of SGLT1, the major carrier
accomplishing intestinal glucose absorption [10].
Accordingly, GA treatment decreases electrogenic
glucose transport in Ussing chamber experiments. It is
noteworthy that the decline of electrogenic glucose
transport following GA treatment did not require the
presence of GA in the experimental solutions during the
Ussing chamber experiments and that the inhibitory effect
of GA on electrogenic intestinal glucose transport thus
cannot be attributed to a direct interaction of GA with the
carrier but results from the decreased SGLT1 protein
abundance in the brush border membrane. According to
the gene array data, the decreased SGLT1 protein
expression is not the result of decreased SGLT1
transcription but may rather be due to posttranscriptional
regulation, such as interference with carrier trafficking
or protein stability. Previous studies have revealed that
SGLT1 may be subject to regulation of transcription [15],
mRNA stability [16], transporter protein abundance in
the plasma membrane [17], and transporter activity [18].
Factors modifying SGLT1 activity include carbohydrate-
rich diet [19], adrenergic innervation [20], insulin [21],
glucagon-like peptide 2 [22], cholecystokinin [17],  insulin-
like growth factors [23], cytosolic Na+ [24] and
lipopolysaccharides [25]. Moreover, SGLT1 activity is
regulated by phosphatidylinositol (PI) 3 kinase [26], the
phosphoinositide-dependent kinase 1 (PDK1) [27] as well
as the serum-and glucocorticoid-regulated kinase isoforms
SGK1 and SGK3 [14, 28], kinases regulating the transport
of a variety of nutrients and channels [14, 28-33]. SGLT1
activity is further subject to downregulation by the 67-
kDa-protein RS1 [11]. According to gene array analysis,
decreased SGLT1 protein abundance could have been
secondary to enhanced expression of RS1 (encoded by
rsc1a1) or secondary to decreased expression of SGK3.
Animals deficient of SGK3 indeed display decreased
intestinal electrogenic glucose transport [14]. The present
observations do not allow safe conclusions regarding the
mechanisms underlying the decreased SGLT1 protein
abundance in the intestinal brush border membrane
following GA treatment.
Previous studies did not yield evidence for a direct
inhibition of intestinal glucose uptake by GA [26]. In those
experiments 2.5 g/l GA was applied directly to perfused
jejunal segments. In our study, addition of GA (100 g/l) to
the perfusate similarly did not inhibit the glucose-induced
short-circuit currents. This observation again excludes
the possibility that the effects of GA are due to direct
inhibition of the carrier or due to chemical interaction and
binding of glucose.
The downregulation of SGLT1 protein expression and
activity were expected to influence plasma and insulin
glucose concentrations. Indeed, the hyperglycemic effect
of excessive glucose intake was significantly blunted by
GA treatment. Moreover, GA treatment prevented the
body weight gain following a four week treatment with
glucose-rich diet despite similar fluid and food intake in
untreated and GA-treated mice. A diet rich in dietary
fibres is associated with reduced body weight [27] and
prevention of metabolic syndrome [28]. In patients with
diabetes mellitus type 2, an increased intake of dietary
fibers improved glycemic control and reduced hyper-
insulinemia [29]. Proposed explanations for the beneficial
effects of dietary fibers include interaction with food intake
and body weight through satiety, glycemia and insulinemia,
blood lipids and blood pressure [30]. Interactions with
intestinal glucose uptake have hitherto not been explored.
In view of the present observations, other dietary fibers
may be similarly effective at least in part by decreasing
SGLT1 activity.
In summary, the dietary fiber GA inhibits intestinal
glucose absorption via interaction with the membrane
abundance of SGLT1. The effect could serve to prevent
obesity and the development of metabolic syndrome.
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